High affinity immunoglobulin epsilon receptor subunit alpha (FceRI-alpha) (FceRI)

The High affinity immunoglobulin epsilon receptor subunit alpha (FceRI-alpha) is the primary ligand-binding component of the high-affinity IgE receptor complex, expressed predominantly on the surface of mast cells and basophils. It plays a pivotal role in the initiation of allergic responses by binding the Fc region of immunoglobulin E (IgE) antibodies with nanomolar affinity. Upon encounter with a multivalent allergen, the IgE-FceRI complexes undergo cross-linking, which triggers an intracellular signaling cascade leading to the release of inflammatory mediators like histamine, leukotrienes, and cytokines. This receptor is a central therapeutic target in various IgE-mediated disorders, including allergic asthma and chronic spontaneous urticaria. While direct pharmacological inhibition of the receptor itself is an area of active research, the most successful clinical approach to date involves the use of monoclonal antibodies like Omalizumab, which sequester free IgE to prevent its interaction with FceRI-alpha. This treatment effectively reduces the sensitivity of effector cells and gradually decreases the surface expression of the receptor, thereby mitigating the severity of allergic inflammation and hypersensitivity reactions.

Other names

Fc epsilon receptor IaFcepsilonRI alpha chainFCER1AFc fragment of IgE, high affinity I, receptor for; alpha polypeptideHigh affinity IgE receptorIgE Fc receptor subunit alpha

Drugs targeting this pathway primarily act through the sequestration of free serum IgE, which prevents the ligand from binding to the FceRI-alpha subunit on effector cells. This sequestration not only blocks immediate mast cell and basophil activation but also leads to the significant downregulation of surface receptor density over time. Experimental antibodies and Fab fragments (e.g., NPB311) may also directly bind to the alpha subunit to competitively inhibit IgE binding without triggering receptor cross-linking.